A Study of Supaglutide in Chinese Type 2 Diabetes Patients

Inclusion criteria

• Have diagnosed with type 2 diabetes for at least 3 months before enrollment.
• Have diet and exercise intervention only (for part A and part B) or been treated with stable dose of metformin as monotherapy for at least 3 months (for part B only)
• Have HbA1c ≥7.0% and ≤10.0% as assessed by the central laboratory.
• Have a body mass index (BMI) of 20-40 kilograms per square meter (kg/m^2).

Exclusion criteria

• Type 1 diabetes (T1D).
• Evidences of fasting C-peptide levels<0.81 ng/mL.
• History of trauma, infection or surgery within a month;
• History of blood donation, blood transfusion or losing more than 450 ml blood within 3 months.
• History of the severe cardiovascular conditions, gastrointestinal diseases, blood system diseases, pancreatitis, or malignant tumors.
• Evidence of abnormal thyroid function within 6 months before screening.
• Positive test results in HBsAg, HCVAB, HIVAB or TPAB.
• History of serious mental illness.
• History of drug or alcohol abuse.
• History of a transplanted organ, acquired or congenital immune system diseases.
• Allergy to active ingredients or excipients of the test drug.
• Evidence of abnormal result of laboratory examination according to the judgment of researchers.
• Participated in any interventional medical, surgical, or pharmaceutical study within 3 months prior to entry into the study.
• Previously completed or withdrawn from this study after providing informed consent.